KETOLAG 2.5% Price

Overview

Welcome to Dwaey, specifically on KETOLAG 2.5% Gel page.
This medicine contains an important and useful components, as it consists of Ketoprofen.
KETOLAG 2.5% is available in the market in concentration 25 mg/g and in the form of Gel.

LAGAP SA is the producer of KETOLAG 2.5% and it is imported from UAE, The most popular alternatives of KETOLAG 2.5% are listed downward .

Mode Of Action

Ketoprofen exhibits anti-inflammatory, analgesic and antipyretic properties. It potently inhibits the enzyme cyclooxygenase resulting in prostaglandin synthesis inhibition.

Indication

• Rheumatic disorders
• Pain and inflammation
• Musculoskeletal and joint disorders

Precaution

History of GI disease (e.g. bleeding or ulcer). Hypertensive patients; renal or hepatic impairment. Pregnancy, lactation, elderly. Monitoring Parameters Close monitoring of BP during initiation and throughout the therapy. Complete blood cell count, chemistry profile, liver and renal function test performed periodically for patients receiving long-term ketoprofen therapy.

Side Effects

• >10% Increased liver function test (up to 15%)
• Dyspepsia (12%) 1-10% Dizziness (3-9%)
• Headache (3-9%)
• Impaired renal function disorder (3-9%)
• Upper GI ulcers
• 3-6 mth treatment; 2-4%
• 1 yo treatment)
• Nausea (>3%)
• Diarrhea (>3%)
• Abdominal pain (>3%)
• Constipation (>3%)
• Flatulence (>3%)
• Rash (1-3%)
• Stomatitis (1-3%)
• Insomnia (1-3%)
• Malaise (1-3%)
• Depression (1-3%)
• Ketoprofen-induced peptic ulcer
• GI bleeding (>2% in long-term studies);
• Peripheral edema (2%)
• Bronchospasm (<2%)
• Myocardial infarction (<2%) <1% Congestive heart failure (<1%)
• Hypertension (<1%)
• Scaling eczema
• Stevens-Johnson syndrome (<0.1%)
• Gastrointestinal hemorrhage (<1%)
• Gastrointestinal perforation (<1%)
• Melena (<1%)
• Agranulocytosis (<1%)
• Anemia (<1%)
• Thrombocytopenia (<1%)
• Hepatitis (<1%)
• Anaphylactoid reaction (<1%)
• Immune hypersensitivity reaction
• Cerebrovascular accident
• Interstitial nephritis (<1%)
• Renal failure (<1%) Potentially Fatal: Anaphylaxis
• exfoliative dermatitis
• Stevens-Johnson syndrome
• toxic epidermal necrolysis.

Contra indication

For all routes: Hypersensitivity to aspirin or other NSAIDs or those suffering from asthma, angioedema, urticaria or rhinitis. Active GI disease (e.g. bleeding or ulcer). Severe heart failure, and renal insufficiency. Treatment of perioperative pain in the setting CABG surgery. Rectal: Patients w/ history of proctitis or haemorrhoids.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Pregnancy Category: B; D in 3rd trimester or near delivery.